Briefly, a total of 6 monkeys were experimentally infected with either hamster-passaged (2 macaques, phase 1) or monkey-passagedB

Briefly, a total of 6 monkeys were experimentally infected with either hamster-passaged (2 macaques, phase 1) or monkey-passagedB. to be 99.98% in volunteer blood donors (n= 28,740) from areas considered to have low endemicity forB. microti. The sensitivity of the prototype test was studied in experimentally infected macaques; a total of 128 samples were detected as positive whereas 125 were detected as positive with an indirect fluorescent antibody (IFA) test; additionally, 83 (89.2%) of the PCR-positive samples were detected in contrast to 81 (87.1%) using an IFA test. All PCR-positive samples that tested negative in the prototype antibody test were preseroconversion period samples. Following seroconversion, periods of intermittent parasitemia occurred; 17 PCR-negative samples drawn in between PCR-positive bleed dates tested positive both by the prototype test (robust reactivity) and IFA test (marginal reactivity) prior to the administration of therapeutic drugs, indicating JAK3-IN-2 that the PCR test failed to detect samples from persistently infected macaques. The prototype assay detected 56 of 58 (96.6%) human subjects diagnosed with clinical babesiosis by both PCR and IFA testing. Overall, the prototype anti-Babesiaassay provides a highly sensitive and specific test for the diagnosis ofB. microtiinfection. While PCR is preferred for detection of window-period parasitemia, antibody tests detect infected subjects during periods of low-level parasitemia. == INTRODUCTION == Babesia microti, an intraerthrocytic protozoan parasite, is a member of theBabesiagenus (phylumApicomplexa, orderPiroplasmida) primarily transmitted to humans through the bite of the deer tick (Ixodes scapularis), endemic to the northeastern and upper-midwestern regions of the United States. Though mostB. microtiinfections are asymptomatic, in some cases, mild to severe malaria-like illness (babesiosis) characterized by fever, chills, myalgia, fatigue, hepatosplenomegaly, and hemolytic anemia have been reported (1). The symptoms can be severe, especially among splenectomized, immunocompromised, or elderly individuals, with mortality rates up JAK3-IN-2 to 5% (2,3). Since January 2011, when babesiosis became a nationally notifiable disease, the CDC has been monitoring the number of cases. Between 2011 and 2014, the number of babesiosis cases reported ranged from 911 to 1 1,761 cases annually, with 2013 and 2014 representing the largest numbers of cases at 1,761 and 1,744, respectively (4). For 2014, 94% of the babesiosis cases were reported from seven states (New York, Connecticut, Massachusetts, Rhode Island, New Jersey, Minnesota, and Wisconsin) considered to be areas of endemicity forB. microti(4). In the early 1980s, it was recognized that blood donors harboringB. microtican transmit the parasite to recipients (5). A subsequent study reported 159 cases of transfusion-transmitted babesiosis (TTB) due toB. microtiand 3 cases due toBabesia duncanibetween 1979 and 2009 (6). Approximately 87% of the TTB index cases occurred in the seven states whereB. microtiis endemic. A more recent compilation of TTB cases indicates that there have been more than 256 cases reported (7). The estimated risk of TTB in selected counties of endemicity is 1 per 101,000 donations, with greater risk in counties of high endemicity (8). The number of transfusion-associatedB. microticases is likely much higher as many cases are either not recognized or not reported. Currently,B. microtiis the highest-ranking transfusion-transmitted pathogen for which there is no blood donor screening test in the United States, and it is the leading cause of transfusion-associated death attributed to an infectious pathogen (9). Additionally, organ transplantation has been implicated inB. microtitransmission as recipients of renal allografts from an untested organ donor have transmittedB. microti(10). Currently, there are no licensed molecular or serologic tests to screen blood donors forB. microti. The most widely used method for diagnosis of infection is an indirect fluorescent antibody (IFA) test which employsB. microtiparasitized erythrocytes as the antigen source (1113). While the IFA test is useful, the assay is labor-intensive, not standardized or automated, and not easily adaptable to modern blood screening practices. The IFA assay has been estimated to have 88 to 96% sensitivity and 90 to 100% specificity (11), which may not meet current expectations for blood screening (14). Tests for the detection of active babesiosis include nucleic acid tests (NATs) and blood smear tests. Blood smear tests are not as sensitive as molecular tests and are not suitable for blood Rabbit polyclonal to ACK1 screening. Molecular tests target the 18S rRNA gene ofB. microtiin infected whole red blood cells (1519). It is estimated that less than 1% of erythrocytes are parasitized early in the course of infection, and the proportion JAK3-IN-2 can vary throughout infection (20), with more cases detected via molecular testing than by blood smear. Two investigational assays (the Immunetics enzyme immunoassay [EIA] and Imugen arrayed fluorescence immunoassay [AFIA]), designed to detect antibodies toB. microti, are under consideration for use in blood screening. Seroprevalence studies using these investigational assays in areas of endemicity and nonendemicity showed rates ranging from 0.28.